A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo

• 全文链接
• 请求原文

作   者：

Hussein N.,Al-Ali;  Scott J.,Crichton;  Charlene,Fabian;  Chris,Pepper;  David R.,Butcher;  Fiona C.,Dempsey;  Christopher N.,Parris; 

作者机构：

School of Life Science;  Anglia Ruskin University;  1 Lochrin Square;  Falmer;  Faculty of Science and Engineering;  Brighton and Sussex Medical School;  Medical Research Building;  Medannex Ltd; 

期刊名称：

Oncogene

i s s n：

0950-9232

年卷期：

2024 年 43 卷 8 期

页   码：

608-614

页   码：

摘   要：

Abstract In this study we conducted the first investigation to assess the efficacy of a novel therapeutic antibody developed to target annexin-A1 (ANXA1). ANXA1 is an immunomodulatory protein which has been shown to be overexpressed in, and promote the development and progression of, several cancer types. In particular, high ANXA1 expression levels correlate with poorer overall survival in pancreatic and triple-negative breast cancers, two cancers with considerable unmet clinical need. MDX-124 is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2).